Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PrecigenPGEN +1.81%53 EV-to-EBITDA is -18.16 as of Sep. 16, 2026. GuruFocus rates PGEN with a GF Score™ of 53/100 and a GF Value™ of $14.93 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 425 Biotechnology companies, Precigen ranks worse than 235293.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Precigen's enterprise value is $2,611.86 Mil.
Precigen's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-143.84 Mil. Therefore, Precigen's EV-to-EBITDA for today is -18.16.
The historical rank and industry rank for Precigen's EV-to-EBITDA or its related term are showing as below:
PGEN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -956.43 Med: -7.35 Max: -1.2
Current: -18.16
During the past 13 years, the highest EV-to-EBITDA of Precigen was -1.20. The lowest was -956.43. And the median was -7.35.
PGEN's EV-to-EBITDA is ranked worse than 100% of 425
companies
in the Biotechnology industry
Industry Median: 12.66
vs PGEN: -18.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Precigen's share price for today is $7.135.
Precigen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Precigen's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Precigen's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precigen EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precigen's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Precigen's EV-to-EBITDA falls into.
Precigen's current Enterprise Value is $2,611.86 Mil.
Precigen's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Precigen (PGEN) has a EV-to-EBITDA of -18.16 as of Sep. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Precigen. According to the industry distribution chart, Precigen ranks #999999 out of 425 companies in the Biotechnology industry.
Is Precigen's EV-to-EBITDA too high?
Precigen's current EV-to-EBITDA is -18.16. Based on the distribution chart, Precigen ranks #999999 out of 425 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Precigen has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Precigen's EV-to-EBITDA compare to PHVS and NKTR?
According to the Biotechnology industry distribution chart, Precigen ranks #999999 out of 425 companies for EV-to-EBITDA. This places Precigen in the lower half of its industry. The industry median EV-to-EBITDA is 12.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.66, based on 425 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Precigen. For the Biotechnology industry, the median EV-to-EBITDA is 12.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precigen's current EV-to-EBITDA is -18.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (PGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $14.93, compared to a current price of $7.14 — trading 52.2% below its estimated fair value. The current EV-to-EBITDA is -18.16. Precigen's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Precigen (PGEN), the current EV-to-EBITDA is -18.16 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precigen (PGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Precigen stock appears to be undervalued.
The current stock price of $7.14 is trading 52.2% below its estimated GF Value™ of $14.93.
GuruFocus considers Precigen to be Possible Value Trap.
Key valuation signals for PGEN:
EV-to-EBITDA: -18.16
GF Value™: $14.93 vs. price of $7.14 (52.2% below fair value)
No single metric tells the full story. See the PGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
53GF Score
Get the complete analysis for PGEN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PGEN has been successfully added to your 
